Market Closed

GTBP
GT Biopharma
$ 3.72
-3.13%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago

GT Biopharma News

Latest GT Biopharma Stock News & GTBP Headlines

GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma
2 months ago | globenewswire.com
GT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy Transcript
2 months ago | seekingalpha.com
GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026
2 months ago | globenewswire.com
GT Biopharma Reports Second Quarter 2026 Financial Results
3 months ago | globenewswire.com
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
5 months ago | globenewswire.com
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
5 months ago | globenewswire.com
The $13 Million Company Teaching the Immune System to Hunt Cancer
6 months ago | prnewswire.com
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
6 months ago | prnewswire.com
GT Biopharma Reports First Quarter 2026 Financial Results
6 months ago | globenewswire.com
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
6 months ago | globenewswire.com
Load More

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

GTBP
GT Biopharma
$ 3.72
-3.13%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago